The management of preterm labour

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 92, Issue 2, 2007, Pages

  Chatterjee, Jayanta ^a   Gullam, Joanna ^b   Vatish, Manu ^b   Thornton, Steve ^b  

^a WATFORD GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ATOSIBAN; BETAMETHASONE; CLINDAMYCIN; CORTICOSTEROID; DEXAMETHASONE; ERYTHROMYCIN; FIBRONECTIN; HYDROXYPROGESTERONE; INDOMETACIN; METRONIDAZOLE; MIFEPRISTONE; NIFEDIPINE; PLACEBO; RITODRINE; UTERUS SPASMOLYTIC AGENT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DELIVERY; DRUG DOSAGE FORM COMPARISON; DRUG INHIBITION; DRUG SAFETY; GESTATIONAL AGE; HUMAN; META ANALYSIS; PATIENT SELECTION; PREMATURE LABOR; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SCREENING TEST; SYSTEMATIC REVIEW; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VAGINITIS;

CERCLAGE, CERVICAL; FEMALE; HUMANS; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PROGESTERONE; RISK FACTORS; TOCOLYTIC AGENTS; VAGINOSIS, BACTERIAL;

EID: 33947204177     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2005.082289     Document Type: Review

References (58)

1. Mercer BM, Goldenberg RL, Das A, et al. The preterm prediction study: a clinical risk assessment system. Am J Obstet Gynecol 1996;174:1885-93.
2. Honest H, Bachmann LM, Gupta JK, et al. Accuracy of cervicovaginal fetal fibronectin in predicting the risk of spontaneous preterm birth: systematic review. BMJ 2002;325:301-11.
3. Shennan A, Jones G, Hawken J, et al. Fetal fibronectin test predicts delivery before 30 weeks of gestation in high risk women, but increases anxiety. Br J Obstet Gynecol 2005;112:293-98.
4. Heath VC, Souka AP, Erasmus I. Cervical length at 23 weeks of gestation: prediction of spontaneous preterm delivery. Ultrasound Obstet Gynecol 1998;12:312-17.
5. Berghella V, Pereira L, Gariepy A, et al. Prior cone biopsy: prediction of preterm birth by cervical ultrasound - an observational study. Am J Obstet Gynecol 2004;191:1393-97.
6. Owen J, Yost N, Berghella V, et al. Can shortened mid-trimester cervical length predict early spontaneous preterm birth? An observational study. Am J Obstet Gynecol 2004;191:298-303.
7. de Carvalho MH, Bittar RE, Brizot ML, et al. Prediction of preterm delivery in the second trimester. Obstet Gynecol 2005;105:532-6.
8. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. N Engl J Med 2000;342:534-40.
9. Ugwumadu A, Manyonda I, Reid F, et al. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 2003;361:983-8.
10. Lamont RF, Duncan SL, Mandal D, et al. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol 2003;101:516-22.
11. Hauth JC, Goldenberg RL, Andrews WW, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995;333:1732-6.
12. Morales WJ, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. Am J Obstet Gynecol 1994;171:345-7.
13. Mc Donald H, Brocklehurst P, Parsons J, et al. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2003;(2):CD000262.
14. Shennan A, Crawshaw S, Briley A, et al. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET study. Br J Obstet Gynaecol 2006;113:65-74.
15. Daya S. Efficacy of progesterone support for pregnancy in women with recurrent miscarriage: a meta-analysis of controlled trials. Br J Obstet Gynaecol 1989;96:275-80.
16. Goldstein P, Berrier J, Rosen S, et al. A meta-analysis of randomized trials of progestational agents in pregnancy. Br J Obstet Gynaecol 1989;96:265-74.
17. Keirse MJ. Progesterone administration in pregnancy may prevent delivery. Br J Obstet Gynaecol 1990;97:149-54.
18. Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379-85.
19. da Fonseca EB, Bittar RE, Carvalho MH, et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomised, placebo-controlled double-blind study. Am J Obstet Gynecol 2003;1888:419-24.
20. Elovitz M, Wang Z. Medroxyprogesterone acetate, but not progesterone, protects against inflammation-induced parturition and intrauterine fetal demise. Am J Obstet Gynecol 2004;190:693-701.
21. Sanchez-Ramos L, Kaumitz AM, Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet Gynecol 2005;105:273-79.
22. Dodd JM, Crowther CA, Cincotta R, et al. Progesterone supplementation for prevention of preterm birth: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2005;84:526-33.
23. MRC/RCOG Working Party on Cervical Cerclage. Final report of the Medical Research Council/Royal College of Obstetricians and Gynaecologists- multicentre randomised trial of cervical cerclage. Br J Obstet Gynaecol 1993;100:516-23.
24. Drakeley AJ, Roberts D, Alfirevic Z, et al. Cervical cerclage for prevention of preterm birth: meta-analysis of randomized trials. Obstet Gynecol 2003;102:621-7.
25. Belej-Rak T, Okun N, Windrim R, et al. Effectiveness of cervical cerclage for a sonographically shortened cervix: a systemic review and meta-analysis. Am J Obstet Gynecol 2003;189:1679-87.
26. Heath VC, Souka AP, Erasmus I, et al. Cervical length at 23 weeks of gestation: the value of Shirodkar suture for the short cervix. Ultrasound Obstet Gynecol 1998;12:318-22.
27. Althuisius SM, Dekker GA, Hummel P, et al. Final results of the Cervical Incompetence Prevention Randomized Cerclage Trial (CIPRACT): therapeutic cerclage with bed rest versus bed rest alone. Am J Obstet Gynecol 2001;185:1106-12.
28. Rust OA, Atlas RO, Jones KJ, et al. A randomized trial of cerclage versus no cerclage among patients with ultrasonographically detected second-trimester preterm dilatation of the internal os. Am J Obstet Gynecol 2000;183:830-5.
29. To MS, Alfirevic Z, Heath VC, et al. Cervical cerclage for the prevention of preterm delivery in women with short cervix: Randomised controlled trial. Lancet 2004;363:1849-53.
30. Berghella V, Odibo AO, To S Meekai, et al. Cerclage for short cervix on Ultra sonography. Meta-analysis of trials using individual patient-level data. Obstet Gynecol 2005;106:181-9.
31. Kenyan SL, Taylor DJ, Tarnow-Mordi W. ORACLE Collaborative group. Broad-spectrum antibiotics for spontaneous preterm labour: The ORACLE I randomized trial, Lancet 2001;357:979-88.
32. Kenyon SL, Taylor DJ, Tarnow-Mordi W. Antibiotics for preterm premature rupture of the membranes. Cochrane Database Syst Rev 2001;(4):CD001058.
33. Kenyon SL, Taylor DJ, Tarnow-Mordi W. ORACLE Collaborative group. Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomized trial, Lancet 2001;357:989-94.
34. Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev 2002;(4):CD000065.
35. Sinclair JC. Meta-analysis of randomised controlled trials of antenatal corticosteroid administration for the prevention of respiratory distress syndrome: discussion. Am J Gynecol 1995;173:335-44.
36. Baud O, Foix-L'Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leucomalacia in very premature infants. N Engl J Med 1999;341:1190-6.
37. Egerman RS, Mercer BM, Doss JL, et al. A randomized controlled trial of oral and intramuscular dexamethasone in the prevention of neonatal respiratory distress syndrome. Am J Obstet Gynecol 1998;179:11120-3.
38. Doyle LW, Ford GW, Richards AL, et al. Antenatal corticosteroids and outcome at 14 years of age in children with birth weight of less than 1501 grams. Pediatrics 2000;106:2.
39. AB, Haas HS, Koppe JG. Twenty-year follow-up of antenatal corticosteroid treatment. Pediatrics 2000;105:77.
40. French NP, Hagan R, Evans SF, et al. Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol 1999;180:114-21.
41. Newnham JP, Moss TJ, Nitsos I, et al. Antenatal corticosteroids: the good, the bad and the unknown. Curr Opin Obstet Gynecol 2002;14:607-12.
42. Gyetvai K, Hannah ME, Hodnett ED, et al. Tocolysis for preterm labour: a systematic review. Obstet Gynecol 1999;94:869- 77.
43. Royal College of Obstetricians and Gynaecologists. Tocolytic drugs for women in preterm labour. Clinical Guidelines No. 1(B) 2002.
44. Papatsonis DN, Van Geijn HP, Ader HJ, et al. Nifedipine and ritodrine in the management of preterm labour: a randomised multi-centre trial. Obstet Gynecol 1997;90:230-4.
45. King JF, Flenady V, Papatsonis DN, et al. Calcium channel blockers for inhibiting preterm labour. Cochrane Database Syst Rev, 2003.10.1002/14651858.CD002255..
46. van Veen AJ, Pelinck MJ, Van Pampus MG, et al. Severe hypotension and fetal death due to tocolysis with nifedipine. Br J Obstet Gynaecol 2005;112:509-510.
47. Vaast P, Dubreucq-Fossaert S, Houfflin-Debarge V, et al. Acute pulmonary oedema during nicardipine therapy for preterm labour; report of five cases. Eur J Obstet Gynecol Reprod Biol 2004;113:98-9.
48. Blanks AM, Vatish M, Allen MJ, et al. Paracrine oxytocin and estradiol demonstrate a spatial increase in human intrauterine tissue with labour. J Clin Endocrinol Metab 2003;88:3392-400.
49. Romero R, Chaiworapongsa T, Goncalves LF. Oxytocin antagonists for tocolysis. In: Critchley H, Bennett P, Thornton S, eds. Preterm birth. London: RCOG press, 2004, ISBN1-900364-92-1..
50. R, Sibai BM, Sanchez-Ramos L, et al. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labour: a randomised, double-blind controlled trial with tocolytic rescue. Am J Obstet Gynecol 2004;182:1173-83.
51. Moutquin JM, Sherman D, Cohen H, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicentre effectiveness and safety study. Am J Obstet Gynecol 2000;182:1191-9.
52. French/Australian Atosiban Investigators Group. Treatment of preterm labour with the oxytocin antagonist atosiban: a double-blind, randomised, controlled comparison with salbutamol. Eur J Obstet Gynecol Reprod Biol 2001;98:177-85.
53. The European Atosiban Study Group. The oxytocin antagonist atosiban versus the B-agonist Terbutaline in the treatment of preterm labour. A randomised, double-blind, controlled study. Acta Obstet Gynecol Scand 2001;80:413-22.
54. The Worldwide Atosiban versus Beta-agonists Study Group. Effectiveness and safety of the oxytocin antagonist versus beta-adrenergic agonists in the treatment of preterm labour. Br J Obstet Gynaecol 2001;108:133-42.
55. Kashanian M, Akbarian AR, Soltanzadeh M, et al. Atosiban and nifedipine for the treatment of preterm labour. Int J Gynaecol Obstet 2005;91:10-14.
56. Al-Omari WR, Al-Shammaa HB, Al-Tikriti EM, et al. Atosiban and nifedipine in acute tocolysis: a comparative study. Eur J Obstet Gynecol Reprod Biol, 2006; Epub ahead of print PMID, 16446025.
57. Papatsonis D, Flenady V, Cole S, et al. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Revi. 2005; (3): CD004452, doi:10.1002/14651858.CD004452.pub2..
58. Coomarasamy A, Ellen M Knox, Harry Gee, et al. Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour; a meta-analysis with an indirect comparison of randomised trials. Br J Obstet Gynecol 2003;110:1045-9.